Liisa Hurme - Orion Oyj Chairman
ORINY Stock | USD 28.63 0.49 1.74% |
Chairman
Dr. Liisa Hurme was appointed Senior Vice President, Supply Chain at Orion Oyj, effective as of January 1, 2019. She has also been Chairman of the Board of Fermion Oy at the Company since January 1, 2014. She was Member of the Executive Management Board of the Company since January 1, 2008. She no longer serves as Senior Vice President, Specialty Products effective as of January 1, 2019. She has held the position since January 1, 2014. She served as Senior Vice President, Proprietary Products at the Company from January 1, 2008 until January 1, 2014. She joined the Company in 1999 as Researcher and Project Manager, Hormonal therapies, and held the position until 2001. Later on, she moved to Project Manager position and in 2002 was appointed Portfolio Manager. After two years, she became Program Leader of pharmaceutical development projects for Hormonal and Urological therapies and was appointed Head of Urology and Oncology business in 2005. Prior to Orion, she worked for Pharmacia Upjohn as Researcher at Diagnostics Unit, Sweden, and as Researcher, Development projects at ELIAS GmbH, Germany, and Institute Pasteur, France. She was Member of the Board of Directors of Finnish Bioindustries FIB and Pharmaservice Oy Member of the Economic Social Policy Committee of the European Federation of Pharmaceutical Industries and Associations EFPIA, as well as Member of the Healthcare Sector Committee of the National Emergency Supply Organization . She holds Doctorate in Philosophy degree in Biochemistry from the University of Helsinki, Faculty of Science, 1996. since 2019.
Age | 56 |
Tenure | 6 years |
Professional Marks | Ph.D |
Phone | 358 10 4261 |
Web | https://www.orion.fi |
Orion Oyj Management Efficiency
The company has return on total asset (ROA) of 0.2077 % which means that it generated a profit of $0.2077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4065 %, meaning that it generated $0.4065 on every $100 dollars invested by stockholders. Orion Oyj's management efficiency ratios could be used to measure how well Orion Oyj manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | CHAIRMAN Age | ||
Jennifer Taubert | Johnson Johnson | 61 | |
Alex Gorsky | Johnson Johnson | 64 | |
Enrico Vanni | Novartis AG ADR | 70 | |
Ashley McEvoy | Johnson Johnson | 50 | |
Robert JD | Merck Company | 58 | |
Carlos Alban | AbbVie Inc | 55 | |
Kenneth Frazier | Merck Company | 67 | |
Alex Krauer | Novartis AG ADR | 69 | |
Leif Johansson | AstraZeneca PLC ADR | 68 | |
Richard Gonzalez | AbbVie Inc | 71 | |
Albert DVM | Pfizer Inc | 63 | |
Robert Michael | AbbVie Inc | 55 | |
Joaquin Duato | Johnson Johnson | 62 | |
Giovanni Caforio | Bristol Myers Squibb | 56 | |
Thibaut Mongon | Johnson Johnson | 51 | |
Joerg Reinhardt | Novartis AG ADR | 65 | |
Daniel Vasella | Novartis AG ADR | 65 | |
Paulus Stoffels | Johnson Johnson | 57 | |
Robert Bradway | Amgen Inc | 62 | |
Daniel ODay | Gilead Sciences | 60 |
Management Performance
Return On Equity | 0.41 | |||
Return On Asset | 0.21 |
Orion Oyj ADR Leadership Team
Elected by the shareholders, the Orion Oyj's board of directors comprises two types of representatives: Orion Oyj inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orion. The board's role is to monitor Orion Oyj's management team and ensure that shareholders' interests are well served. Orion Oyj's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orion Oyj's outside directors are responsible for providing unbiased perspectives on the board's policies.
Terhi Ormio, VP Communications | ||
Liisa Hurme, Senior Vice President Specialty Products and Chairman of the Board of Fermion Oy; Member of the Executive Management Board | ||
MBA M, Sr Board | ||
Juhani Kankaanpaa, Sr Board | ||
Olli LlM, Gen Functions | ||
Tuukka MSc, Investor Officer | ||
Timo Lappalainen, President CEO, Chairman of the Executive Management Board | ||
Pr MD, Sr Board | ||
MSc MSc, Sr Board |
Orion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Orion Oyj a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.41 | |||
Return On Asset | 0.21 | |||
Profit Margin | 0.26 % | |||
Operating Margin | 0.33 % | |||
Current Valuation | 7.28 B | |||
Shares Outstanding | 280.4 M | |||
Price To Earning | 22.24 X | |||
Price To Book | 5.50 X | |||
Price To Sales | 7.54 X | |||
Revenue | 1.04 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Orion Pink Sheet Analysis
When running Orion Oyj's price analysis, check to measure Orion Oyj's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orion Oyj is operating at the current time. Most of Orion Oyj's value examination focuses on studying past and present price action to predict the probability of Orion Oyj's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orion Oyj's price. Additionally, you may evaluate how the addition of Orion Oyj to your portfolios can decrease your overall portfolio volatility.